



## **Seres Therapeutics to Host First Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on May 2, 2019**

April 29, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 29, 2019-- [Seres Therapeutics, Inc.](https://www.businesswire.com/news/home/20190429005615/en/) (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on May 2, 2019 at 8:30 a.m. ET to discuss first quarter 2019 results and provide a general business update.

To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 3368968. To join the live webcast, please visit the "Investors and Media" section of the Seres website at [www.serestherapeutics.com](http://www.serestherapeutics.com).

A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

### **About Seres Therapeutics**

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres' SER-287 program has obtained Orphan Drug designation from the U.S. Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres' SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent *C. difficile* infection. Seres is also developing SER-401 in a Phase 1b study in patients with metastatic melanoma. For more information, please visit [www.serestherapeutics.com](http://www.serestherapeutics.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190429005615/en/>

Source: Seres Therapeutics, Inc.

### **IR or PR Contact:**

Carlo Tanzi, Ph.D., Seres Therapeutics  
Vice President of Investor Relations and Corporate Communications  
[ctanzi@serestherapeutics.com](mailto:ctanzi@serestherapeutics.com)